Want to join the conversation?
$ABBV said it launched VENCLEXTA early in 2Q16 in its initial indication for relapsed/refractory CLL patients with a 17p deletion, which represents a smaller addressable patient population in the US. The company has begun a measured commercial rollout to ensure adequate physician training and expects a modest level of VENCLEXTA sales for 2016.
I haven’t seen a drop in banks like this in a long time. Looks like $WFC is still facing pressures from its sales practices scandal..!!
Helping President-elect's America first focus, $WMT set to create 10,000 retail jobs in the US in 2017.
Looks like Trump has his eyes on the $MON and Bayer merger next. He had a meeting with the CEOs and apparently got job promises from them.